NASDAQ$GDRX
GoodRx Holdings Inc. · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
GoodRx experienced revenue growth and improved profitability, driven by pharma manufacturer solutions and prescription transactions.
GoodRx reported an 8% increase in revenue to $195.3 million and a net income of $4.0 million for Q3 2024, compared to a net loss of $38.5 million in the same period last year. The growth was primarily driven by a 77% increase in pharma manufacturer solutions revenue and a 4% increase in prescription transactions revenue.
- Revenue and Adjusted Revenue reached $195.3 million.
- Net income was $4.0 million, with a net income margin of 2.0%.
- Adjusted EBITDA was $65.0 million, resulting in an Adjusted EBITDA Margin of 33.3%.
- The company exited the quarter with over 7 million consumers of prescription-related offerings.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$195M
Revenue by segment
GoodRx · $175M total across 3 segments · Q3 2023
- Prescription Transactions$135M+3.2%77.6%
- Subscription$23.2M-12.5%13.3%
- Pharma Direct$15.9M-35.1%9.1%
Forward guidance
For the fourth quarter of 2024, GoodRx anticipates revenue and Adjusted Revenue of approximately $200 million and Adjusted EBITDA Margin of about 34%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro